3.4 Other prognostic factors for the survival of pediatric NHL
K-M analysis was also performed to investigate the impact of other
clinicopathological features on the survival of pediatric NHL. NHL
subtype, CNS involvement, stage, and risk were significantly associated
with EFS or OS. Despite there being no significant difference in 5-year
OS rate among the four NHL subtypes (BL, 85.9%; DLBCL, 96.4%; LBL
83.5%; ALCL,84.6%; P =0.404;Fig. 3B), the 5-year EFS rate
(P = 0.013; Fig. 3A) in ALCL (49.0%) was remarkably lower than
that in BL (79.0%; P = 0.021), DLBCL (87.4%; P = 0.005),
and LBL (76.7%; P = 0.006). Patients with CNS involvement at
diagnosis had a similar 5-year EFS rate (74.7% vs. 69.0%; P =
0.115; Fig. 3C), but had a significantly lower 5-year OS rate (68.5%
vs. 87.6%; P = 0.004; Fig. 3D) than those without. Significant
differences were found for both the 5-year EFS rate (89.0% vs.
72.2%;P = 0.011;Fig. 4A) and OS rate (100% vs. 83.7%;P = 0.013;Fig. 4B) between patients with early (stage I/II) and
advanced (stage III/IV) disease. Patients with early-stage disease had
better survival than those with advanced -stage disease. Similarly, the
very low/low-risk group had significantly better survival than the
intermediate/high-risk group: the 5-year EFS rate was 91.3% and 70.8%
(P = 0.002; Fig. 4C), respectively, and the 5-year OS rate was
98.3% and 83.0% (P = 0.009; Fig. 4D), respectively.